Capital Insights
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns
Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]
The ‘Unused Billion’: How Points4Purpose is Disrupting the Flatlining Loyalty Market
The loyalty industry is plagued by “sameness,” leaving billions in value dormant. Ivan Schwartz’s Points4Purpose is disrupting this flatlining market by turning rewards into a liquid currency for rent, bills, and over 1.8 million charities.
1,000km, sustainable, efficient , no onboard pilot: How ‘Gap Drone ’ is rewriting the rules of remote logistics
Can autonomous drones solve Australia’s “tyranny of distance”? GAP Drone CEO Liesl Haris thinks so. With the launch of ATLAS—an autonomous transport logistics aircraft system—the company is bypassing traditional infrastructure to deliver 50kg payloads over 1,000km. Dubbed the “Uber of airfreight,” GAP Drone is tackling the “too hard basket” of remote logistics, partnering with Australia Post to provide First Nations communities and regional hubs with reliable, low-cost access to medicine, food, and economic opportunity. By operating within current regulatory frameworks and utilising a “no-runway” launch model, GAP Drone is transforming air freight from an expensive luxury into a scalable utility.
Precision Care, Zero Clicks: Why the Future of the NDIS is Voice-First
Carelogix is solving the healthcare burnout crisis by replacing manual typing with a sophisticated AI “care co-pilot.” By reclaiming nearly half of a caregiver’s day, the platform offers a significant value inflection point for providers and investors in the trillion-dollar care economy.
The Private Equity Signal I Am Watching Very Closely
Pattern recognition in private markets is not about predicting the future. It is about reading what is already moving before the wider market notices. I spotted the same signal in life sciences 18 months before it became consensus. We are watching it happen again, this time in private equity.
The Australian Life Science Sector: A Structural Convergence of 5 Critical Factors
For a decade, we have watched the foundation being built. Government grants are flowing into research infrastructure. Labs constructed. IP portfolios are growing. Talent returning from global pharma. For most of that decade, the returns were slow, the timelines were long, and the capital was cautious. That era is over. The Australian life science sector […]
The Private Capital Infrastructure Is Failing High-Growth Companies
The Broken Reality of Capital Raising Infrastructure Venture capital poured 55% of global funding into AI companies in 2025. Seed and Series A rounds saw 70% of capital flow to AI-related opportunities. The capital is available. The demand is clear. But the infrastructure connecting founders to investors remains unchanged. Deal flow arrives through LinkedIn messages, […]
What Active Private Market Investors Told Us They Want in 2026
We just released the 2026 Investor Survey, the most comprehensive look at what private market investors are actually thinking and prioritizing as they deploy capital this year. Key data challenges assumptions, revealing that nearly 68% of the active investor base are individuals, not institutions.
The Better Pill to Swallow: Solving the $60B Drug Delivery Problem with AI
While most biotechs hunt for new molecules, BCS2 is fixing the ones we already have. Founder Stuart Gunzburg explains how his AI-powered platform transforms “insoluble” blockbuster drugs into rapid-acting sprays and films, creating a de-risked, high-speed pathway to market for a $60 billion opportunity.
Backed By Leading Investment Groups and Family Offices
